Patent Application: Combination Pharmacological Interventions for Sleep Apnea

This document is a published patent application from the USPTO, not a regulatory rule or guidance. It describes a novel combination pharmacological intervention for treating obstructive sleep apnea, involving specific classes of drugs: a norepinephrine reuptake inhibitor (NRI), a muscarinic receptor antagonist, and a carbonic anhydrase inhibitor. The application, identified as US20260083709A1, was filed on December 3, 2025, and published on March 26, 2026.

As this is a patent application, it does not impose immediate regulatory obligations or compliance deadlines on entities. However, it signals potential future developments in sleep apnea treatment that pharmaceutical companies and drug manufacturers may wish to monitor for competitive or licensing purposes. The inventors are listed as Lawrence G. MILLER, Ronald FARKAS, D. Andrew WELLMAN, Luigi TARANTO-MONTEMURRO, and Scott Aaron SANDS.